Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
Noosa News24 hours agoElectrify your vehicle, home or business at Noosa’s EV & Electrify Everything Expo
-
Noosa News22 hours agoQueensland plan to increase lethal shark control measures goes against advice of government-commissioned report
-
Noosa News22 hours agoDrought pushes farmers’ mental health to the brink across southern Australia
-
Noosa News18 hours agoAustralia’s newest rice mill funded largely by farmers